We demonstrate that [Cp*Rh] complexes bearing substituted 2,2'-bipyridyl ligands are effective hydrogen evolution catalysts (Cp*=η -pentamethylcyclopentadienyl). Disubstitution (at the 4 and 4' positions) of the bipyridyl ligand (namely -tBu, -H, and -CF ) modulates the catalytic overpotential, in part due to involvement of the reduced ligand character in formally rhodium(I) intermediates. These reduced species are synthesized and isolated here; protonation results in formation of complexes bearing the unusual η -pentamethylcyclopentadiene ligand, and the properties of these protonated intermediates further govern the catalytic performance. Electrochemical studies suggest that multiple mechanistic pathways are accessible, and that the operative pathway depends on the applied potential and solution conditions. Taken together, these results suggest synergy in metal-ligand cooperation that modulates the mechanisms of fuel-forming catalysis with organometallic compounds bearing multiple non-innocent ligands.

Background Iron depletion/deficiency in blood donors frequently results in deferrals for low hemoglobin, yet blood centers remain reluctant to dispense iron replacement therapy to donors. Study Design and Methods During a 39-month period, 1236 blood donors deferred for hemoglobin <12.5 g/dL and 400 non-deferred control donors underwent health history screening and laboratory testing (CBC, iron studies). Iron depletion and deficiency were defined as ferritin of 9–19 mcg/L and <9 mcg/L in females and 18–29 mcg/L and <18 mcg/L in males. Deferred donors and iron-deficient control donors were given a 60-pack of ferrous sulfate 325 mg tablets, and instructed to take one tablet daily. Another 60-pack was dispensed at all subsequent visits. Results In the low hemoglobin group, 30% and 23% of females and 8% and 53% of males had iron depletion or deficiency, respectively, compared with 29% and 10% of females and 18% and 21% of males in the control group. Iron depleted/deficient donors taking iron showed normalization of iron-related laboratory parameters, even as they continued to donate. Compliance with oral iron was 68%. Adverse gastrointestinal effects occurred in 21% of donors. The study identified 13 donors with serious medical conditions, including eight with GI bleeding. No donors had malignancies or hemochromatosis. Conclusion Iron depletion or deficiency was found in 53% of female and 61% of male low hemoglobin donors, and in 39% of female and male control donors. Routine administration of iron replacement therapy is safe, effective, and prevents the development of iron depletion/deficiency in blood donors.

Background Pica and restless legs syndrome (RLS) are associated with iron depletion and deficiency. The presence of pica and RLS was prospectively assessed in blood donors. Methods During a 39-month period, 1236 donors deferred for fingerstick hemoglobin <12.5 g/dL and 400 non-deferred “control” donors underwent health screening and laboratory testing (CBC, ferritin, iron, transferrin). Pica and RLS were assessed by direct questioning. Deferred donors and iron-deficient control donors were given ferrous sulfate 325 mg daily for 60 days. Reassessments were performed and additional iron tablets dispensed at subsequent visits. Results Pica was reported in 11% of donors with iron depletion/deficiency, compared with 4% of iron-replete donors (p<0.0001). Pagophagia (ice pica) was most common and often of extraordinary intensity. Female sex, younger age, and lower MCV and transferrin saturation values were strongly associated with pica. Donors with pica given iron reported a marked reduction in the desire to consume the non-nutritive substance by day 5–8 of therapy, with disappearance of symptoms by day 10–14. RLS was reported in 16% of subjects with iron depletion/deficiency compared with 11% of iron-replete donors (p=0.012). Iron replacement generally resulted in improvement of RLS symptoms, however, at least 4–6 weeks of iron therapy was necessary. Conclusion The presence of pica is associated with a high probability of iron depletion/deficiency in blood donors; however, RLS lacks a strong correlation in this population. Screening questions for pagophagia may be useful in the ascertainment of iron deficiency in donors and may identify those who would benefit from oral iron.

A series of [Cp*Rh] complexes (Cp* = η5-pentamethylcyclopentadienyl) bearing the κ2-[P,N]-8-(diphenylphosphino)­quinoline (PQN) ligand have been prepared and characterized. Chemical or electrochemical reduction of the rhodium­(III) form generates an isolable rhodium­(I) complex; this rhodium­(I) complex reacts with a range of organic acids to yield a rhodium­(III) hydride bearing [Cp*] in the η5 mode and [PQN] in the expected κ2 mode. Solid-state structures of these three compounds from X-ray diffraction studies reveal only small changes in the intraligand bond distances across the series, suggesting the redox events associated with interconversion of these compounds are primarily metal centered. Cyclic voltammetry data show that the rhodium­(III) chloride complex undergoes a two-electron reduction at −1.19 V vs ferrocenium/ferrocene, whereas the analogous solvento rhodium­(III) acetonitrile complex undergoes two sequential one-electron reductions. The rhodium­(III) hydride undergoes an irreversible, ligand-centered reduction near −1.75 V vs ferrocenium/ferrocene. Carrying out this reduction alone or in the presence of added of triethylammonium as a source of protons results in only modest yields of H2, as shown by bulk electrolyses and chemical reduction experiments. These results are discussed in the context of recent work with [Cp*Rh] complexes bearing more symmetric 2,2′-bipyridyl and diphosphine ligands.